Bioequivalence Study of Lu AF35700
Launched by H. LUNDBECK A/S · Jan 8, 2018
Trial Information
Current as of August 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy men and women aged ≥18 and ≤55 years
- • Body Mass Index (BMI) of ≥18.5 and ≤32 kg/m2
- • Subject must be in good general health as assessed using medical history, clinical laboratory tests, and physical examination
- Exclusion Criteria:
- • The subject must not be of childbearing potential (if a woman) or should use contraception, be surgically sterilized or not be sexually active (both sexes). Women must not be pregnant or lactating
- • The subject must not be a CYP2D6 or a CYP2C19 poor metaboliser
- • The subject has previously been dosed with Lu AF35700
- • Other protocol defined inclusion and exclusion criteria may apply
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, , United Kingdom
Patients applied
Trial Officials
Email contact via H.Lundbeck A/S
Study Director
LundbeckClinicalTrials@Lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials